SLVNF (Solvonis Therapeutics) 6-1 Month Momentum %: N/A% (As of Aug. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Solvonis Therapeutics 6-1 Month Momentum %?

Solvonis Therapeutics SLVNF -58.33% 6-1 Month Momentum % is N/A% as of Aug. 28, 2026. The stock has 4 warning signs investors should review. Among 1,374 Biotechnology companies, Solvonis Therapeutics ranks worse than 71.47% on this metric.

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-08-28), Solvonis Therapeutics's 6-1 Month Momentum % is N/A%.

The industry rank for Solvonis Therapeutics's 6-1 Month Momentum % or its related term are showing as below:

SLVNF's 6-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -16.47
* Ranked among companies with meaningful 6-1 Month Momentum % only.

Solvonis Therapeutics  (OTCPK:SLVNF) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Solvonis Therapeutics 6-1 Month Momentum % Related Terms

Solvonis Therapeutics  (OTCPK:SLVNF) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-1 Month Momentum % →
What does a 6-1 Month Momentum % of N/A% mean?
Solvonis Therapeutics (SLVNF) has a 6-1 Month Momentum % of N/A% as of Aug. 28, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Solvonis Therapeutics and its competitors. According to the industry distribution chart, Solvonis Therapeutics ranks #982 out of 1374 companies in the Biotechnology industry, placing it in the top 71.5%.
Is Solvonis Therapeutics' 6-1 Month Momentum % too high?
Solvonis Therapeutics' current 6-1 Month Momentum % is N/A%. Based on the distribution chart, Solvonis Therapeutics ranks #982 out of 1374 companies in the Biotechnology industry, which is below the industry midpoint.
How does Solvonis Therapeutics' 6-1 Month Momentum % compare to ?
According to the Biotechnology industry distribution chart, Solvonis Therapeutics ranks #982 out of 1374 companies for 6-1 Month Momentum %. This places Solvonis Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Biotechnology company?
A good 6-1 Month Momentum % depends on the Biotechnology industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Solvonis Therapeutics and its competitors. Solvonis Therapeutics's current 6-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solvonis Therapeutics stock overvalued right now?
Solvonis Therapeutics (SLVNF) has a current 6-1 Month Momentum % of N/A%. The current 6-1 Month Momentum % is N/A%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Solvonis Therapeutics (SLVNF), the current 6-1 Month Momentum % is N/A% as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Solvonis Therapeutics Business Description

Comparable Companies
Other Exchanges SVNS:UKJ4I:Germany
Address Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry. The products in company's pipeline include SVN-001, SVN-002, SVN-015. SVN-114, and others.